OPEN END-TURBO-OPTIONSSCHEIN - GILEAD SCIENCES | Real-time BOERSE MUENCHEN 05:36:56 2024-06-20 EDT | ||
| 15.79 EUR | +0.25% |
|
| Current month | -0.13% | ||
| 1 month | -18.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 15.79 | +0.25% |
| 24-06-19 | 15.75 | +1.55% |
| 24-06-18 | 15.51 | -8.66% |
| 24-06-17 | 16.98 | -2.08% |
| 24-06-14 | 17.34 | +10.17% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 05:36 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | HSBC |
| WKN | TR3M5C |
| ISIN | DE000TR3M5C6 |
| Date issued | 2018-05-07 |
| Strike | 46.5 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 19.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 43.87 € |
|---|---|
| Lowest since issue | 10.74 € |
| Spread | 0.3 € |
| Spread % | 1.87% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.15
USD
Average target price
82.7
USD
Spread / Average Target
+30.95%
- Stock Market
- Certificates
- Certificat
